10-Q: Greenwich LifeSciences Reports Q1 2025 Results, Cites Ongoing Clinical Trial and ATM Offerings

Greenwich LifeSciences reports a net loss for Q1 2025, driven by increased research and development and general and administrative expenses, while continuing to advance its Phase III clinical trial and utilize at-the-market (ATM) offerings for financing.

Summary

• Greenwich LifeSciences, Inc. reported its financial results for the first quarter of 2025.
• The company is focused on its Phase III clinical trial, Flamingo-01, evaluating GLSI-100 for preventing breast cancer recurrences.
• For the three months ended March 31, 2025, the company's net loss was $3,258,362, or $0.25 per share, compared to a net loss of $2,473,195, or $0.19 per share, for the same period in 2024.
• Research and development expenses increased by 19% to $2,601,122, and general and administrative expenses increased by 99% to $681,210.
• The company's cash balance as of March 31, 2025, was $2,749,959, compared to $4,091,990 as of December 31, 2024.
• The company has been utilizing at-the-market (ATM) offerings to raise capital, issuing and selling shares of its common stock.
• Between January 1, 2025, and March 31, 2025, the company completed ATM offerings, issuing 39,918 shares at an average price of $12.52 per share, resulting in net proceeds of $492,423.
• Between April 1, 2025, and May 9, 2025, the company completed additional ATM offerings, issuing 175,657 shares at an average price of $9.58 per share, resulting in net proceeds of $1,635,498.
• The company's ability to continue operations is dependent on obtaining additional capital.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While the company is progressing with its clinical trial, the increased net loss, decreased cash balance, and reliance on ATM offerings raise concerns about its financial stability. The company also reported material weaknesses in internal controls.

Positives

• The company is actively progressing its Phase III clinical trial, Flamingo-01, for its breast cancer immunotherapy.
• The company has successfully utilized ATM offerings to raise capital.
• The company is expanding its Flamingo-01 trial into Europe, increasing its global reach.

Negatives

• The company experienced a larger net loss in Q1 2025 compared to Q1 2024.
• The company's cash balance decreased significantly during the quarter.
• The company is dependent on raising additional capital to continue operations, raising concerns about its financial stability.
• The company's disclosure controls and procedures were not effective as of such date as a result of material weaknesses in our internal control over financial reporting due to inadequate segregation of duties within account processes due to limited personnel and insufficient written policies and procedures for accounting, IT and financial reporting and record keeping.

Risks

• The company's ability to continue as a going concern is dependent on obtaining additional capital.
• The company's clinical trials may not be successful.
• The company may face challenges in securing regulatory approval for its product candidate.
• The company operates in a competitive and rapidly changing environment.
• The company's disclosure controls and procedures were not effective as of such date as a result of material weaknesses in our internal control over financial reporting due to inadequate segregation of duties within account processes due to limited personnel and insufficient written policies and procedures for accounting, IT and financial reporting and record keeping.

Future Outlook

The company expects to continue to incur significant expenses and corresponding increased operating losses for the foreseeable future as it continues to develop its pipeline, conduct clinical trials, seek regulatory approval, and prepare to commercialize its product candidate. The company will also experience increased costs associated with operating as a public company.

Management Comments

• We are currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.

Industry Context

Greenwich LifeSciences is operating in the competitive biopharmaceutical industry, specifically focused on developing immunotherapies for breast cancer. The company's success depends on the outcome of its clinical trials and its ability to secure funding and regulatory approvals.

Comparison to Industry Standards

• It is difficult to compare Greenwich LifeSciences directly to industry standards without knowing the specifics of their clinical trial design and stage of development.
• However, other companies in the immunotherapy space, such as BioNTech and Moderna, have achieved significant success with their mRNA-based therapies.
• Greenwich LifeSciences' approach of using a peptide-based immunotherapy is different and may have its own advantages and disadvantages.
• The company's reliance on ATM offerings for funding is common among smaller biotech companies, but it can also dilute existing shareholders.
• AstraZeneca and Novartis are examples of large pharmaceutical companies that are also investing heavily in breast cancer therapies.

Related Party Transactions

• Unreimbursed expenses have been accrued and incurred by management, which total $ 84,362 as of March 31, 2025 and $ 75,916 as of December 31, 2024.
• Bonus compensation of $ 306,281 for senior management for services provided in 2024 has been deferred.
• The month-to-month sub-lease is from a related party and the underlying lease expires in July of 2026.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and decreased cash balance.
• Employees may be affected by the company's financial situation and potential need for additional capital.
• Patients may benefit from the company's development of a new breast cancer immunotherapy.
• Suppliers and creditors may be affected by the company's ability to meet its financial obligations.

Next Steps

• Continue expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
• Continue to develop the drug in the company's pipeline.
• Continue planning and preparing for clinical trials.
• Continue general and administrative activities associated with the company's operations.
• Remediate the material weaknesses in internal control over financial reporting.

Key Dates

Keywords

Greenwich LifeSciences, GLSI-100, Flamingo-01, Breast Cancer, Immunotherapy, Clinical Trial, ATM Offering, Financial Results, GP2, HER2/neu